If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT02480881","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"http://","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":"true"},"PatientLevelData":"false","SharingIpd":"None","acronym":"","allocation":"N/A","arm_groups":[{"arm_group_label":"Single Sequence A, B, C, and D","arm_group_description":"Treatment A/Cycle 1: OC containing EE and progestin taken by mouth. Treatment B/Cycle 2: OC containing EE and progestin taken by mouth. Treatment C/Cycle 3: Loestrin 1.5/30 taken by mouth. Treatment D/Cycle 4: Loestrin 1.5/30 (alone) and Loestrin 1.5/30 with BMS-663068 taken by mouth.","arm_type":"Experimental"}],"assignment":"Single Group Assignment","brief_summary":"This is an open-label, single sequence, 4-cycle, 4-treatment, drug-drug interaction (DDI) study in healthy female subjects on oral contraceptives (OC). There is no formal research hypothesis to be statistically tested. It is expected that coadministration of BMS-663068 with OC will not affect the pharmacokinetics (PK) of either ethinyl estradiol (EE) or norethindrone (NE).","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:36:32","criteria":"Inclusion Criteria: - Healthy female nonsmoking subjects, ages 18 to 40 years, inclusive with a body mass index of 18.0 kg/m2 to 32.0 kg/m2, inclusive - Women of child bearing potential with intact ovarian function by medical history and history of regular menstrual cycles must have been on a stable regimen of combination oral contraceptives containing EE and progestin (28 day regimen) without evidence of breakthrough bleeding or spotting for at least 2 consecutive months prior to Day -1 Exclusion Criteria: - Any significant acute or chronic medical illness Other protocol defined exclusion criteria could apply.","detailed_description":"","display_gender":"Female","display_gender_internal":"GENDER_FEMALE","display_phase":"Phase 1","display_phase_internal":"PHASE_1","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"26","exclusion":"","gender":"Female","gender_based":"","gender_description":"","healthy_volunteers":"Yes","id":"541e6cc4-c014-52b9-ad99-3b0aa127a2cc","internal":{"content":null,"contentDigest":"123be4a82a351f97b25293004893d667","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Healthy female nonsmoking subjects, ages 18 to 40 years, inclusive with a body mass index of 18.0 kg/m2 to 32.0 kg/m2, inclusive - Women of child bearing potential with intact ovarian function by medical history and history of regular menstrual cycles must have been on a stable regimen of combination oral contraceptives containing EE and progestin (28 day regimen) without evidence of breakthrough bleeding or spotting for at least 2 consecutive months prior to Day -1 Exclusion Criteria: - Any significant acute or chronic medical illness Other protocol defined exclusion criteria could apply.","interventions":[{"arm_group_label":"Single Sequence A, B, C, and D","intervention_description":"Investigational product","intervention_name":"BMS-663068","intervention_type":"Drug"},{"arm_group_label":"Single Sequence A, B, C, and D","intervention_description":"Subject's existing combination OC tablet containing EE and progestin","intervention_name":"Oral Contraceptive","intervention_type":"Drug"},{"arm_group_label":"Single Sequence A, B, C, and D","intervention_description":"OC containing EE and norethindrone acetate (NEA)","intervention_name":"Loestrin 1.5/30","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":[],"last_follow_up_date":"01/11/2016 00:00:00","links":[],"locations":[{"City":"Miami","Latitude":"25.6993807","CountryDisplay":"United States","Longitude":"-80.2934522","Name":"GSK Investigational Site","StateDisplay":"FL","PostalCode":"33143","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"San Antonio","Latitude":"29.4854054","CountryDisplay":"United States","Longitude":"-98.4513272","Name":"GSK Investigational Site","StateDisplay":"TX","PostalCode":"78209","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"}],"masking":"","maximum_age_raw":"40 years","maximum_age":"40","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 22:44:43","number_of_arms":"1","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"Effect of BMS-663068 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate in Healthy Female Subjects","org_study_id":"206279","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"1","primary_compl_date":"01/11/2016 00:00:00","primary_outcomes":[{"outcome_description":"Pharmacokinetic parameter includes: maximal observed concentration (Cmax) for EE and NE.","outcome_measure":"Pharmacokinetic parameter Cmax","outcome_time_frame":"From Day 21 of Treatment C/Cycle 3 to Day 21 of Treatment D/Cycle 4","outcome_safety_issue":null},{"outcome_description":"Pharmacokinetic parameter includes: area under the concentration-time curve in one dosing interval (AUC(TAU)) for EE and NE.","outcome_measure":"Pharmacokinetic parameter AUC TAU","outcome_time_frame":"From Day 21 of Treatment C/Cycle 3 to Day 21 of Treatment D/Cycle 4","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[{"id":"AI438-019","id_type":"Other Identifier","id_domain":"Bristol-Myers Squibb"}],"secondary_outcomes":[{"outcome_description":"Adverse event monitoring","outcome_measure":"Clinical Safety as Measured by Adverse Event Monitoring.","outcome_time_frame":"From Day 1 (Treatment A/Cycle 1) to Day 22 (Treament D/Cycle 4)","outcome_safety_issue":null},{"outcome_description":"Vital signs assessments","outcome_measure":"Clinical Safety as Measured by the Collection of Vital Signs.","outcome_time_frame":"From Day 1 (Treatment A/Cycle 1) to Day 22 (Treament D/Cycle 4)","outcome_safety_issue":null},{"outcome_description":"12-lead ECGs","outcome_measure":"Clinical Safety as Measured by the Collection of Electrocardiograms (ECGs).","outcome_time_frame":"From Day 1 (Treatment A/Cycle 1) to Day 22 (Treament D/Cycle 4)","outcome_safety_issue":null},{"outcome_description":"Physical examinations","outcome_measure":"Clinical Safety as measured by Physical Examination.","outcome_time_frame":"From Day 1 (Treatment A/Cycle 1) to Day 22 (Treament D/Cycle 4)","outcome_safety_issue":null},{"outcome_description":"clinical chemistry, hematology, and urinalysis.","outcome_measure":"Clinical Safety as Measured by Clinical Laboratory Evaluations.","outcome_time_frame":"From Day 1 (Treatment A/Cycle 1) to Day 22 (Treament D/Cycle 4)","outcome_safety_issue":null},{"outcome_description":"Pharmacokinetic parameter: -time of maximum observed concentration (Tmax) for EE and NE.","outcome_measure":"Pharmacokinetic Parameter","outcome_time_frame":"From Day 21 of Treatment C/Cycle 3 to Day 21 of Treatment D/Cycle 4","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GlaxoSmithKline"]},"start_date":"07/07/2015 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":false}},"pageContext":{"studyId":"206279"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}